

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

July 28, 2022

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services  
25<sup>th</sup> Floor, P. J. Towers,  
Dalal Street, Mumbai-400001  
Script Id: 506365

**Subject: Outcome of Board Meeting Held on Thursday, July 28, 2022**

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. July 28, 2022, have discussed the following matters:

1. Approval of Un-Audited Financial Results of the Company for the quarter ended June 30, 2022 along with the Limited Review Report thereon.
2. Approval of the Notice of the 80<sup>th</sup> Annual General Meeting of the Company to be held on Thursday, September 08, 2022 at 04:00 p.m. at the Registered Office of the Company at 5-Kumud Apartment Co. op. Hsg. Soc. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane- 421301 for the year ended March 31, 2022.
3. Approval of Book Closure date from September 02, 2022 to September 08, 2022 (both days inclusive) and Record Date will be September 01, 2022.
4. Appointment of CS Hemant Shetye, Designated Partner of HSPN & Associates LLP, Company Secretaries, to act as a Scrutinizer for the forthcoming 80<sup>th</sup> Annual General Meeting of the Company.

The Meeting commenced at 04.00 p.m. and concluded at 05.15 p.m.

Thanking You.

Yours Faithfully,

For CHEMO PHARMA LABORATORIES LIMITED

  
BHAVIN SHETH  
CEO & DIRECTOR  
(DIN -00114608)



# Sanjay Rane & Associates

## CHARTERED ACCOUNTANTS

C-403, Marathon Next Gen. Innova,  
Opp. Peninsula Corporate Park,  
Off Ganpatrao Kadam Marg,  
Lower Parel, Mumbai-400 013.

Phone : 49198585  
Telefax : 49198521  
Email : admin@ssrane.net  
Website : www.ssraneandco.com

## LIMITED REVIEW REPORT

To,  
Board of Directors of Chemo Pharma Laboratories Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of CHEMO PHARMA LABORATORIES LIMITED for the quarter ended June 30, 2022 and year to date results for the three months period from April 01, 2022 to June 30, 2022 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates

Chartered Accountants

Firm Reg. No. 121089W



CA. Abhijeet Deshmukh

Partner

Membership No. 129145



Date: July 20, 2022

Place: Mumbai

UDIN: 22129145ANHJBG7456

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

Sr. No.	Particulars	(Rupees in Thousand)			
		Quarter Ended		Year Ended	
		30th June 2022	31st March 2022	30th June 2021	31st March 2022
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations				
II	Other Income	(3,847)	1,288	1,092	7,889
III	<b>Total Revenue (I + II)</b>	<b>(3,847)</b>	<b>1,288</b>	<b>1,092</b>	<b>7,889</b>
IV	<b>Expenses</b>				
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	445	472	352	1,731
	(5) Depreciation and Amortisation Expenses	33	49	-	189
	(6) Administrative and Other Expenses	683	1,340	429	2,320
	(7) Finance Costs	-	-	-	-
	<b>Total Expenses</b>	<b>1,160</b>	<b>1,860</b>	<b>781</b>	<b>4,240</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>(5,007)</b>	<b>(572)</b>	<b>311</b>	<b>3,649</b>
VI	Exceptional Items	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>(5,007)</b>	<b>(572)</b>	<b>311</b>	<b>3,649</b>
VIII	Extra Ordinary Items	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>(5,007)</b>	<b>(572)</b>	<b>311</b>	<b>3,649</b>
X	Tax Expenses				
	(1) Current Tax	-	631	-	631
	(2) Tax Adjustment Previous Year	-	-	-	-
	(3) Deferred Tax Income	-	(296)	-	(296)
	(4) MAT Credit Entitlement	-	(2,285)	-	(2,285)
XI	Profit/(Loss) for the period from continuing operations (IX - X)	<b>(5,007)</b>	<b>1,378</b>	<b>311</b>	<b>5,599</b>
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>(5,007)</b>	<b>1,378</b>	<b>311</b>	<b>5,599</b>
XVI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	B (i) Items that will not be reclassified to profit or loss				
	(ii) Income tax relating to items that will not be reclassified	-	-	-	-
XVII	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>(5,007)</b>	<b>1,378</b>	<b>311</b>	<b>5,599</b>
XVIII	<b>Earnings per Share :</b>				
	(1) Basic	<b>(3.34)</b>	<b>0.92</b>	<b>0.21</b>	<b>3.73</b>
	(2) Diluted				

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Standalone Unaudited Financial Results for the Quarter Ended 30.06.2022 have been reviewed by the Audit Committee in their Meeting held on 28.07.2022 and approved by the Board of Directors of its Meeting held on 28.07.2022. The Limited Review Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo - Pharma Laboratories Limited

Bhavin Sheth

CEO & Director  
DIN : 00114608

Place : Mumbai  
Date : 28th July, 2022



# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2022

(Rs. in Thousand)

PARTICULARS	STANDALONE		
	UNAUDITED QUARTER ENDED 30.06.2022	UNAUDITED QUARTER ENDED 30.06.2021	AUDITED YEAR ENDED 31.03.2022
<b>Reconciliation of Profit After Tax as reported earlier:</b>			
<b>Net Profit / (Loss) for the Period (as per AS)</b>	(84)	311	5,599
<b>Benefit / (Charge):</b>	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-
Impact of Fair Valuation of Financial Instruments	(4,923)	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>(5,007)</b>	<b>311</b>	<b>5,599</b>

For Chemo Pharma Laboratories Ltd.



**Bhavin Sheth**  
CEO & Director  
DIN : 00114608

Mumbai, 28th July, 2022